Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 5/2016

01-05-2016 | Review Article

Adenosine can thwart antitumor immune responses elicited by radiotherapy

Therapeutic strategies alleviating protumor ADO activities

Authors: Prof. Dr. med. Peter Vaupel, M.A., Prof. Dr. rer.nat. Gabriele Multhoff

Published in: Strahlentherapie und Onkologie | Issue 5/2016

Login to get access

Abstract

Background

By studying the bioenergetic status we could show that the development of tumor hypoxia is accompanied, apart from myriad other biologically relevant effects, by a substantial accumulation of adenosine (ADO). ADO has been shown to act as a strong immunosuppressive agent in tumors by modulating the innate and adaptive immune system. In contrast to ADO, standard radiotherapy (RT) can either stimulate or abrogate antitumor immune responses. Herein, we present ADO-mediated mechanisms that may thwart antitumor immune responses elicited by RT.

Materials and methods

An overview of the generation, accumulation, and ADO-related multifaceted inhibition of immune functions, contrasted with the antitumor immune effects of RT, is provided.

Results

Upon hypoxic stress, cancer cells release ATP into the extracellular space where nucleotides are converted into ADO by hypoxia-sensitive, membrane-bound ectoenzymes (CD39/CD73). ADO actions are mediated upon binding to surface receptors, mainly A2A receptors on tumor and immune cells. Receptor activation leads to a broad spectrum of strong immunosuppressive properties facilitating tumor escape from immune control. Mechanisms include (1) impaired activity of CD4 + T and CD8 + T, NK cells and dendritic cells (DC), decreased production of immuno-stimulatory lymphokines, and (2) activation of Treg cells, expansion of MDSCs, promotion of M2 macrophages, and increased activity of major immunosuppressive cytokines. In addition, ADO can directly stimulate tumor proliferation and angiogenesis.

Conclusion

ADO mechanisms described can thwart antitumor immune responses elicited by RT. Therapeutic strategies alleviating tumor-promoting activities of ADO include respiratory hyperoxia or mild hyperthermia, inhibition of CD39/CD73 ectoenzymes or blockade of A2A receptors, and inhibition of ATP-release channels or ADO transporters.
Literature
1.
Gaipl US, Multhoff G, Scheithauer H et al (2014) Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy. Immunotherapy 6:597–610CrossRefPubMed
2.
Demaria S, Pilones KA, Vanpouille-Box C et al (2014) The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat Res 182:170–181CrossRefPubMedPubMedCentral
3.
4.
Frey B, Rubner Y, Kulzer L et al (2014) Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother 63:29–36CrossRefPubMed
5.
Zegers CM, Rekers NH, Quaden DH et al (2015) Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects. Clin Cancer Res 21:1151–1560CrossRefPubMed
6.
Lauber K, Brix N, Ernst A et al (2015) Targeting the heat shock response in combination with radiotherapy: sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity. Cancer Lett 368:209–229CrossRefPubMed
7.
Ma Y, Conforti R, Aymeric L et al (2011) How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev 30:71–82CrossRefPubMed
8.
9.
Georgakilas AG (2015) Role of the immune system and inflammation in ionizing radiation effects. Cancer Lett 368:154–156CrossRefPubMed
10.
Candeias S, Testard I (2015) The many interactions between the innate immune system and the response to radiation. Cancer Lett 356:173–178CrossRef
11.
Hellweg CE (2015) The Nuclear Factor κB pathway: a link to the immune system in the radiation response. Cancer Lett 368:275–289CrossRefPubMed
12.
Apetoh L, Ghiringhelli F, Tesniere A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050–1059CrossRefPubMed
13.
14.
Multhoff G, Pockley AG, Schmid TE et al (2015) The role of heat shock protein 70 (Hsp70) in radiation-induced immunomodulation. Cancer Lett 368:179–184CrossRefPubMed
15.
Twyman-Saint Victor C, Rech AJ, Maity A et al (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373–377CrossRefPubMed
16.
Le QT, Shirato H, Giaccia AJ et al (2015) Emerging treatment paradigms in radiation oncology. Clin Cancer Res 21:3393–3401CrossRefPubMed
17.
Persa E, Balogh A, Safrany G et al (2015) The effect of ionizing radiation on regulatory T cells in health and disease. Cancer Lett 368:252–261CrossRefPubMed
18.
Hekim N, Cetin Z, Nikitaki Z et al (2015) Radiation triggering immune response and inflammation. Cancer Lett 368:156–163CrossRefPubMed
19.
Antonioli L, Hasko G, Fornai M et al (2014) Adenosine pathway and cancer: where do we go from here? Expert Opin Ther Targets 18:973–977CrossRefPubMed
20.
Park HJ, Griffin RJ, Hui S et al (2012) Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 177:311–327CrossRefPubMed
21.
Antonioli L, Blandizzi C, Pacher P et al (2013) Immunity, inflammation and cancer: a leading role for adenosine. Nature Rev Cancer 13:842–857CrossRef
22.
Sitkovsky MV, Kjaergaard J, Lukashev D et al (2008) Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 14:5947–5952CrossRefPubMed
23.
Young A, Mittal D, Stagg J et al (2014) Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov 4:879–888CrossRefPubMed
24.
25.
Hoskin DW, Reynolds T, Blay J (1994) Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumours. Int J Cancer 59:854–855CrossRefPubMed
26.
Vaupel P, Mayer A (2016) Hypoxia-driven adenosine accumulation: a crucial microenvironmental factor promoting tumor progression. Adv Exp Med Biol 876:177–183
27.
Busse M, Vaupel P (1996) Accumulation of purine catabolites in solid tumors exposed to therapeutic hyperthermia. Experientia 52:469–473CrossRefPubMed
28.
Blay J, White TD, Hoskin DW (1997) The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57:2602–2605PubMed
29.
Hatfield SM, Kjaergaard J, Lukashev D et al (2014) Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1alpha-dependent and extracellular adenosine-mediated tumor protection. J Mol Med 92:1283–1292CrossRefPubMedPubMedCentral
30.
31.
Becker JC, Andersen MH, Schrama D et al (2013) Immune-suppressive properties of the tumor microenvironment. Cancer Immmunol Immunother 62:1137–1148CrossRef
32.
Gessi S, Merighi S, Sacchetto V et al (2011) Adenosine receptors and cancer. Biochim Biophys Acta 1808:1400–1412CrossRefPubMed
33.
34.
Muller-Haegele S, Muller L, Whiteside TL (2014) Immunoregulatory activity of adenosine and its role in human cancer progression. Expert Rev Clin Immunol 10:897–914CrossRefPubMed
35.
Fishman P, Bar-Yehuda S, Synowitz M et al (2009) Adenosine receptors and cancer. Handb Exp Pharmacol 193:399–441CrossRefPubMed
36.
Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916–920CrossRefPubMed
37.
Hatfield SM, Kjaergaard J, Lukashev D et al (2015) Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med 7:277ra30CrossRefPubMedPubMedCentral
38.
39.
Bayer C, Shi K, Astner ST et al (2011) Acute versus chronic hypoxia: why a simplified classification is simply not enough. Int J Radiat Oncol Biol Phys 80:965–968CrossRefPubMed
40.
Vaupel P, Mayer A (2014) Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications. Adv Exp Med Biol 812:19–24CrossRefPubMed
41.
42.
Stagg J, Smyth MJ (2010) Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29:5346–5358CrossRefPubMed
43.
Vaupel P (1974) Atemgaswechsel und Glucosestoffwechsel von Implantationsturmoren (DS-Carcinosarkom) in vivo. Funktionsanalyse biologischer Systeme. Steiner, Wiesbaden
44.
Mayer A, Vaupel P (2013) Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? Adv Exp Med Biol 789:203–209CrossRefPubMed
45.
Lardner A (2001) The effects of extracellular pH on immune function. J Leukoc Biol 69:522–530PubMed
46.
Gottfried E, Kreutz M, Mackensen A (2012) Tumor metabolism as modulator of immune response and tumor progression. Semin Cancer Biol 22:335–341CrossRefPubMed
47.
48.
Mendler AN, Hu B, Prinz PU et al (2012) Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. Int J Cancer 131:633–640CrossRefPubMed
49.
Adams JL, Smothers J, Srinivasan R et al (2015) Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov 14:603–622CrossRefPubMed
50.
Häusler SF, Del Barrio IM, Diessner J et al (2014) Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res 6:129–139PubMedPubMedCentral
51.
Iannone R, Miele L, Maiolino P et al (2014) Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res 4:172–181PubMedPubMedCentral
52.
Allard B, Pommey S, Smyth MJ et al (2013) Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 19:5626–5635CrossRefPubMed
53.
54.
Schalper KA, Carvajal-Hausdorf D, Oyarzo MP (2014) Possible role of hemichannels in cancer. Front Physiology 5:237
55.
Vaupel P, Muller-Klieser W, Otte J et al (1984) Impact of various thermal doses on the oxygenation and blood flow in malignant tumors upon localized hyperthermia. Adv Exp Med Biol 169:621–629CrossRefPubMed
56.
Lee CT, Mace T, Repasky EA (2010) Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer? Int J Hypethermia 26:232–246CrossRef
57.
Ban HS, Uto Y, Nakamura l (2011) Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004-2010). Expert Opin Ther Pat 21:131–146
58.
Sitkovsky M, Ohta A (2013) Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. J Mol Med 93:147–155
Metadata
Title
Adenosine can thwart antitumor immune responses elicited by radiotherapy
Therapeutic strategies alleviating protumor ADO activities
Authors
Prof. Dr. med. Peter Vaupel, M.A.
Prof. Dr. rer.nat. Gabriele Multhoff
Publication date
01-05-2016
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 5/2016
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-016-0948-1

Other articles of this Issue 5/2016

Strahlentherapie und Onkologie 5/2016 Go to the issue

Original Article

Seed loss in prostate brachytherapy

Case Study

Radiation recall dermatitis induced by sorafenib

Original Article

Treatment of breast cancer with simultaneous integrated boost in hybrid plan technique

Literatur kommentiert

Ist beim diffus großzelligen B‑Zell-Lymphom im frühen Stadium nach der Chemotherapie eine konsolidierende Strahlentherapie erforderlich?

Literatur kommentiert

Die Bedeutung der kraniellen Bestrahlung als Bestandteil moderner Therapieprotokolle für das Überleben bei Kindern mit akuter lymphoblastischer Leukämie

Original Article

4D-Listmode-PET-CT and 4D-CT for optimizing PTV margins in gastric lymphoma